Alexion Pharmaceuticals, Inc. Share Price and Company Fundamentals



Price
$171.99
Change
0.580 (0.338%)
52 week
94.0 - 173.24

Last traded: Last Wednesday at 8:00 PM

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.

Key Metrics

PE ratio

55.82

PB ratio

3.06

Dividend yield

Beta

1.27

Market cap

$38.01B

Enterprise value

$36.67B

Company profile

Industry / SectorBiotechnology / Healthcare
Full time employees3837
Websitehttp://www.alexion.com
Mailing address121 Seaport Boulevard Boston MA 02210 United States
Phone / Fax475 230 2596 / 203 271 8198

Dividends

Alexion Pharmaceuticals, Inc. does not pay dividends.

Company Executives

As of May 2021, following are the company executives and directors listed on Alexion Pharmaceuticals, Inc..

NameTitleAgeTotal Pay
Dr. Ludwig N. HantsonCEO & Director574.25M
Dr. Aradhana Sarin M.D.Exec. VP & CFO451.75M
Mr. Brian M. GoffExec. VP and Chief Commercial & Global Operations Officer511.76M
Ms. Ellen V. Chiniara J.D., Esq.Exec. VP, Chief Legal Officer & Corp. Sec.611.56M
Dr. John J. OrloffExec. VP and Head of R&D631.83M
Mr. Daniel A. Bazarko CPAChief Accounting Officer & Sr. VP
Mr. Christopher J. Stevo CFAHead of Investor Relations
Ms. Indrani M. Lall FranchiniExec. VP & Chief Compliance Officer48
Megan GoulartSr. Director of Corp. Communications
Ms. Becky LillieInterim Chief Human Experience Officer

Profitability and management effectiveness

Profit margin

10.89%

Operating margin

47.41%

Return on assets

10.08%

Return on equity

4.43%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Alexion Pharmaceuticals, Inc. is 38.01B and its enterprise value is 36.67B. The enterprise value to revenue ratio of ALXN is 5.86.

The ALXN's stocks Beta value is 1.27 making it 27% more volatile compared to NASDAQ market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Frequently Asked Questions

1. What is Alexion Pharmaceuticals, Inc.'s Stock Symbol?

Alexion Pharmaceuticals, Inc. trades on NASDAQ under the ticker symbol "ALXN".

2. What is Alexion Pharmaceuticals, Inc.'s stock price today?

One share of ALXN stock can currently be purchased for approximately $171.99.

3. How can I contact Alexion Pharmaceuticals, Inc.?

Alexion Pharmaceuticals, Inc.'s mailing address is 121 Seaport Boulevard Boston MA 02210 United States. The company can be reached via phone at 475 230 2596.

4. What is Alexion Pharmaceuticals, Inc.'s official website?

The official website of Alexion Pharmaceuticals, Inc. is http://www.alexion.com.